CN112006285A - 一种靶向定植的益生菌粉及其制备方法 - Google Patents
一种靶向定植的益生菌粉及其制备方法 Download PDFInfo
- Publication number
- CN112006285A CN112006285A CN202010819662.7A CN202010819662A CN112006285A CN 112006285 A CN112006285 A CN 112006285A CN 202010819662 A CN202010819662 A CN 202010819662A CN 112006285 A CN112006285 A CN 112006285A
- Authority
- CN
- China
- Prior art keywords
- targeted
- probiotics
- probiotic powder
- powder
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 118
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 118
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 70
- 239000000843 powder Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 31
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 24
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 24
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 12
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 12
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 12
- 241000194017 Streptococcus Species 0.000 claims abstract description 11
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims description 47
- 241000894006 Bacteria Species 0.000 claims description 33
- 239000010410 layer Substances 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 21
- 229920001661 Chitosan Polymers 0.000 claims description 17
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 17
- 239000003094 microcapsule Substances 0.000 claims description 17
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 239000002356 single layer Substances 0.000 claims description 14
- 241001052560 Thallis Species 0.000 claims description 13
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 11
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 11
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 25
- 210000000941 bile Anatomy 0.000 abstract description 7
- 210000004211 gastric acid Anatomy 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 6
- 210000003238 esophagus Anatomy 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000007797 corrosion Effects 0.000 abstract 1
- 238000005260 corrosion Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 18
- 210000000936 intestine Anatomy 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种靶向定植的益生菌粉及其制备方法,涉及保健食品技术领域,所述益生菌粉包括益生菌、益生元和包埋层,所述益生菌包括两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种;本发明解决了服用益生菌粉后食道等环境对益生菌活性的影响,本发明包埋层为不稳定的益生菌提供保护;益生元的生物相容性较好,提高其包埋产率和效率,提高益生菌粉的耐酸、胆汁性能,包埋层和益生元各组分发挥相互协同作用,提高包埋产率和效率,也提高了对胃酸的耐受能力,抵御低pH胃酸侵蚀,避免被胆汁破坏,保证了益生菌靶向定植。
Description
技术领域
本发明涉及保健食品技术领域,尤其涉及一种靶向定植的益生菌粉及其制备方法。
背景技术
益生菌是一类对宿主有益的活性微生物,是定植于人体肠道、生殖系统内,能产生确切健康功效从而改善宿主微生态平衡、发挥有益作用的活性有益微生物的总称。补充益生菌不仅可调理肠胃,还能增强人体免疫力、缓解乳糖不耐乳糖症、预防生殖系统感染,促进肠道消化系统健康,降低血清胆固醇,帮助吸收营养成分,造就健康肠道。近年来的研究表明,人体内的细菌多达1000多种,特别是胃肠道内细菌最为丰富,占全身微生态菌总数80%左右,是人体细胞的10倍,被誉为人类的“第二基因组”。这些发现为益生菌产品在食品、保健品、医药、养殖、环境、卫生用品等领域的应用带来了巨大的推动力。目前,益生菌被广泛用于酸奶、乳酸菌饮料、益生菌粉剂、动物饲料、环境治理等产品中,形成了相对完整和成熟的益生菌行业。需要特殊注意的是,益生菌只有达到一定的数量水平时,益生菌才能在宿主体内产生相应的效果。所以,以益生菌为功能成分的食品、保健品或药品需要保证所含活的益生菌数量保持在一定的水平。这一需求对益生菌的生产和制备提出了相应的要求,现有技术中,益生菌活化培养的方法较为传统,得到的种子液活性不高,导致应用效果较差。因为益生菌的保存条件苛刻,现有产品普遍存在着活菌易死亡,菌数不稳定,导致益生菌产品保质期短,质量不稳定的技术问题。
健康的肠道菌群定植对于早期免疫的形成以及肠道屏障功能的建立具有重要作用,有助于保护宝宝抵御感染和过敏的威胁。益生菌最终发挥作用的地方在消化道的下端,即小肠中下段和大肠内,因此益生菌能否对抗消化道的各种消化液到达目的地--肠壁上,取决于它们的“黏附”和“定植”能力。现有益生菌产品靶向定植能力较差,还未到靶向位置即失去活性。
综上,一种稳定性更高的靶向定植的益生菌粉有待研究。
发明内容
本发明的目的是为了解决现有技术中的问题,而提出的一种靶向定植的益生菌粉及其制备方法。
为了实现上述目的,本发明采用了如下技术方案:
一种靶向定植的益生菌粉,所述益生菌粉包括益生菌、益生元和包埋层,所述益生菌包括两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种。
优选的,所述益生元包括水苏糖和低聚半乳糖。
优选的,两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种的质量比为2-3:1-2:1-3:1-2:1-1.5。
优选的,水苏糖和低聚半乳糖的质量比为1:2-3,所述水苏糖与两歧双歧杆菌的质量比为4-7:1-2。
优选的,所述包埋层包括聚-L-精氨酸和壳聚糖。
优选的,聚-L-精氨酸和壳聚糖的质量比为1:2-4,所述壳聚糖与两歧双歧杆菌的质量比8-10:1-2。
优选的,所述益生菌粉中活菌量为109-1010CFU/g。
优选的,所述复合益生菌为粉剂。
优选的,靶向定植的益生菌粉的制备方法为:
S1、菌体制备:将益生菌的菌种活化后培养,生长至稳定期终止发酵,离心后收集菌体;
S2、菌悬液制备:在菌体中加入益生元得到菌悬液;
S3、包埋层制备:将菌悬液与包埋层混合搅拌,得到单层微囊菌液;
S4、菌粉制备:将单层微囊菌液冻干处理,制得靶向定植的益生菌粉。
双歧杆菌具有维护肠道正常细菌菌群平衡,抑制病原菌的生长,防止便秘,下痢和胃肠障碍等;抗肿瘤;在肠道内合成维生素、氨基酸和提高机体对钙离子的吸收;降低血液中胆固醇水平,防治高血压;改善乳制品的耐乳糖性,提高消化率;增强人体免疫机能,抗衰老,延年益寿。增强机体的非特异和特异性免疫反应;控制体内毒素血症的作用;提高宿主对放射线的耐受性。
嗜热链球菌只能到达小肠的上半部,而不像双歧杆菌那样可以去到大肠。科学家认为活的的酸奶菌嗜热链球菌都能帮助乳糖不耐受的人们消化乳糖,因为这种菌可以产生能乳糖酶。
嗜酸链球菌,是某些乳酸链球菌产生的一种多肽物质。可被人体内的酶降解、消化,是一种高效、安全、无毒、无副作用的天然食品防腐剂。它能抑制多数革兰氏阳性菌,尤其对产生芽孢的革兰氏阳性菌如枯草芽孢杆菌、嗜热脂肪芽孢杆菌等有很强的抑制作用。
长双歧杆菌主要定植于肠道下端,生长需要弱酸性环境,48小时就能进入生长稳定期。其特有的果糖-6-磷酸解酮酶将葡萄糖分解为醋酸和乳酸,降低肠道的pH值,抑制外籍菌的生长、繁殖。研究表明长双歧杆菌产生的短链脂肪酸如乙酸、丙酸具抗菌活性,对假单胞菌属、金葡菌有抗菌作用。从而抑制了肠道中有害菌和致病菌的生长。而且双歧杆菌属于专性厌氧菌,在厌氧条件下,它的生长速度超过兼性厌氧菌,因而在营养物质有限的情况下,专性厌氧菌可优势生长,而通常兼性厌氧的潜在致病菌处于劣势状态。作为肠道优势菌,它的益生功能显着,能紧密定植在肠粘膜,发挥营养肠道、阻碍有害菌定植、调节免疫、平衡菌群、修复受损肠屏障的功能。
保加利亚酸奶中的乳酸菌,在分类上属于乳酸杆菌,因其菌种产地、微生物特性、效能优异等特点,被微生物学家命名为德氏乳杆菌保加利亚亚种(简称保加利亚乳杆菌)。效能优异,助人健康长寿。能发酵糖而获得能量,产生大量乳酸。
食用者吞食上述菌株后,该菌株从口腔至肠胃会经过多个器官,食道和胃中酸性物质会大量破坏菌株的活性,使得最后进入肠道的活性菌株所剩无几,所以提高菌株的靶向定植效果是至关重要的。
本方案的菌株组合组成了一个在不同条件下都能生长快、作用持久的联合菌群,在整个肠黏膜表面形成一道生物屏障,抑制肠内有害菌,使肠道功能得以改善。另外,双歧杆菌双联活菌在人体肠内发酵后可产生乳酸和醋酸,能提高钙、磷、铁的利用率,促进铁和维生素D的吸收,并产生维生素B1、B2、B6、B12及丙氨酸、缬氨酸、天冬氨酸和苏氨酸等人体必需的营养物质,对于人体具有不容忽视的重要营养作用。
水苏糖是天然存在的一种四糖,是一种可以显著促进双歧杆菌等有益菌增殖的功能性低聚糖。纯品为白色粉末,味稍甜,甜度为蔗糖的22%,味道纯正,无任何不良口感或异味。
低聚半乳糖是一种具有天然属性的功能性低聚糖,其分子结构一般是在半乳糖或葡萄糖分子上连接1~7个半乳糖基,即Gal-(Gal)n-Glc/Gal(n为0-6)。
聚-L-精氨酸和壳聚糖,可提高微胶囊的生物相容性,进一步提高益生菌的定位释放的能力,进一步最大限度保持组合物的稳定性、活性和有效定植率,有效防止使用及储存过程中益生菌活性的降低。
所以本方案的益生菌菌株种类的组合本身即是一种能生长快、作用持久的联合菌群,在整个肠黏膜表面形成一道生物屏障,抑制肠内有害菌,使肠道功能得以改善。该益生菌组合物在肠道内与宿主肠上皮细胞结合的过程,其首先是宿主的特异性,来自人体的细菌不一定能在动物体内定植,同样来自动物的细菌也不一定能在人体定植;其次是菌株的特异性,同一种属的细菌有的菌株可以黏附定植,有的则不可以;另外,还需有足够的量,黏附有群体效应,细菌只有达到一定的量,黏附才能牢固;所以本方案的益生菌菌株无论是从菌株组合本身还是菌株组合的量,均达到使其与宿主肠上皮细胞结合的技术效果。同时黏附可避免益生菌被胃酸、胆汁等胃肠道分泌的液体和肠道的蠕动所清除,而粘黏后的菌同时减少了其他有害菌的粘黏的可能性。同时形成了生物屏障,防止有害菌接近肠道的上皮细胞。黏附后的菌株定植,在黏附膜表面形成微生物膜,防止外籍菌入侵,保护肠粘膜的健康。嗜酸乳杆菌、双歧杆菌等均具有较强的黏附、定植和适应消化道环境的能力。
同时本方案通过添加益生元和包埋层等辅助组分,该组分的包覆,使得益生菌菌株组合物在食用到进入人体肠道的过程中,即使部分益生元和包埋层被效果分解,但是相较于现有技术中直接服用益生菌,大部分益生菌菌株的活性得以保留,进而便于其后续在宿主肠上皮细胞的粘附,提高益生菌菌株的靶向定植率。
与现有技术相比,本发明提供了一种靶向定植的益生菌粉及其制备方法,具备以下有益效果:
1、本发明中的制备方法工艺简单,降低了生产成本,保障产业化能够获得良好的收益;并且本发明的制备方法对益生菌的包埋效率高、包埋效果好;
2、本发明解决了服用益生菌粉后食道等环境对益生菌活性的影响,本发明包埋层为不稳定的益生菌提供保护;益生元的生物相容性较好,提高其包埋产率和效率,提高益生菌粉的耐酸、胆汁性能,包埋层和益生元各组分发挥相互协同作用,提高包埋产率和效率,也提高了对胃酸的耐受能力,抵御低pH胃酸侵蚀,避免被胆汁破坏,保证了益生菌靶向定植;
3、益生元和包埋层可提高微胶囊的生物相容性,提高了益生菌的靶向定植效果,保持组合物的稳定性、活性和有效定植率,有效防止使用及储存过程中益生菌活性的降低;
4、本发明中的益生元有助于调理肠胃,可直达肠道,不受酸性胃液腐蚀破坏,产生挥发性脂肪酸,降低肠道pH,直接促活、增殖益生菌群,间接抑制有害菌的生长,保护肠道微生态;
5、本发明的益生菌组合,经过特殊处理,有利于提高益生菌的活性,更利于有效调节肠道菌群平衡、改善机体免疫力。
具体实施方式
下面将结合本发明实施例中,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。
实施例1:
一种靶向定植的益生菌粉及其制备方法,包括以下步骤:
S1、菌体制备:按配比称量益生菌,两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种的质量比为2:1:1:1:1,将益生菌的菌种活化后培养,生长至稳定期终止发酵,离心后收集菌体,所述益生菌粉中活菌量为109-1010CFU/g;
S2、菌悬液制备:在菌体中加入益生元得到菌悬液,水苏糖和低聚半乳糖的质量比为1:2,所述水苏糖与两歧双歧杆菌的质量比为4:1;
S3、包埋层制备:将菌悬液与包埋层混合搅拌,得到单层微囊菌液,聚-L-精氨酸和壳聚糖的质量比为1:2,所述壳聚糖与两歧双歧杆菌的质量比8:1;
S4、菌粉制备:将单层微囊菌液冻干处理,制得靶向定植的益生菌粉。
实施例2:
一种靶向定植的益生菌粉及其制备方法,包括以下步骤:
S1、菌体制备:按配比称量益生菌,两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种的质量比为3:2:3:2:1.5,将益生菌的菌种活化后培养,生长至稳定期终止发酵,离心后收集菌体,所述益生菌粉中活菌量为109-1010CFU/g;
S2、菌悬液制备:在菌体中加入益生元得到菌悬液,水苏糖和低聚半乳糖的质量比为1:3,所述水苏糖与两歧双歧杆菌的质量比为7:2;
S3、包埋层制备:将菌悬液与包埋层混合搅拌,得到单层微囊菌液,聚-L-精氨酸和壳聚糖的质量比为1:4;所述壳聚糖与两歧双歧杆菌的质量比10:2;
S4、菌粉制备:将单层微囊菌液冻干处理,制得靶向定植的益生菌粉。
实施例3:
一种靶向定植的益生菌粉及其制备方法,包括以下步骤:
S1、菌体制备:按配比称量益生菌,两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种的质量比为2.5:1.5:2:1.5:1,将益生菌的菌种活化后培养,生长至稳定期终止发酵,离心后收集菌体,所述益生菌粉中活菌量为109-1010CFU/g;
S2、菌悬液制备:在菌体中加入益生元得到菌悬液,水苏糖和低聚半乳糖的质量比为1:2.5,所述水苏糖与两歧双歧杆菌的质量比为5.5:1.5;
S3、包埋层制备:将菌悬液与包埋层混合搅拌,得到单层微囊菌液,聚-L-精氨酸和壳聚糖的质量比为1:3;所述壳聚糖与两歧双歧杆菌的质量比9:1.5;
S4、菌粉制备:将单层微囊菌液冻干处理,制得靶向定植的益生菌粉。
实施例4:
一种靶向定植的益生菌粉及其制备方法,包括以下步骤:
S1、菌体制备:按配比称量益生菌,两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种的质量比为2:1:3:1:1.5,将益生菌的菌种活化后培养,生长至稳定期终止发酵,离心后收集菌体,所述益生菌粉中活菌量为109-1010CFU/g;
S2、菌悬液制备:在菌体中加入益生元得到菌悬液,水苏糖和低聚半乳糖的质量比为1:2-3,所述水苏糖与两歧双歧杆菌的质量比为7:1;
S3、包埋层制备:将菌悬液与包埋层混合搅拌,得到单层微囊菌液,聚-L-精氨酸和壳聚糖的质量比为1:2;所述壳聚糖与两歧双歧杆菌的质量比8:1;
S4、菌粉制备:将单层微囊菌液冻干处理,制得靶向定植的益生菌粉。
实施例5:
一种靶向定植的益生菌粉及其制备方法,包括以下步骤:
S1、菌体制备:按配比称量益生菌,两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种的质量比为3:1:3:1:1.5,将益生菌的菌种活化后培养,生长至稳定期终止发酵,离心后收集菌体,所述益生菌粉中活菌量为109-1010CFU/g;
S2、菌悬液制备:在菌体中加入益生元得到菌悬液,水苏糖和低聚半乳糖的质量比为1:3,所述水苏糖与两歧双歧杆菌的质量比为4:2;
S3、包埋层制备:将菌悬液与包埋层混合搅拌,得到单层微囊菌液,聚-L-精氨酸和壳聚糖的质量比为1:4;所述壳聚糖与两歧双歧杆菌的质量比10:2;
S4、菌粉制备:将单层微囊菌液冻干处理,制得靶向定植的益生菌粉。
对比例1:
本对比例1中益生菌粉中没有添加益生元,将菌株简单混合然后包埋即可;其余步骤均匀实施例1一致。
对比例2:
本对比例2中的益生菌粉中没有添加包埋层,将菌株和益身元简单混合即可;其余步骤均匀实施例1一致。
对比例3:
本对比例3中的益生菌粉中没有添加益生元和包埋层,将菌株简单混合即可;其余步骤均匀实施例1一致。
对上述实施1-5,和对比例1-3的制备后的靶向定植的益生菌粉进行活菌含量试验测试。
结果如下表1所示:
参照上述实施例1-5,对照例1-3和表1中的实验数据可以得出,相较对照例1-3,本方案的靶向定植的益生菌粉活菌含量更高,解决了服用益生菌粉后食道等环境对益生菌活性的影响,本发明包埋层为不稳定的益生菌提供保护;益生元的生物相容性较好,提高其包埋产率和效率,提高益生菌粉的耐酸、胆汁性能,包埋层和益生元各组分发挥相互协同作用,提高包埋产率和效率,也提高了对胃酸的耐受能力,抵御低pH胃酸侵蚀,避免被胆汁破坏,保证了益生菌靶向定植;益生元和包埋层可提高微胶囊的生物相容性,提高了益生菌的靶向定植效果,保持组合物的稳定性、活性和有效定植率,有效防止使用及储存过程中益生菌活性的降低;本发明中的益生元有助于调理肠胃,可直达肠道,不受酸性胃液腐蚀破坏,产生挥发性脂肪酸,降低肠道pH,直接促活、增殖益生菌群,间接抑制有害菌的生长,保护肠道微生态;本发明的益生菌组合,经过特殊处理,有利于提高益生菌的活性,更利于有效调节肠道菌群平衡、改善机体免疫力。本发明中的制备方法工艺简单,降低了生产成本,保障产业化能够获得良好的收益;并且本发明的制备方法对益生菌的包埋效率高、包埋效果好。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (8)
1.一种靶向定植的益生菌粉,其特征在于,所述益生菌粉包括益生菌、益生元和包埋层,所述益生菌包括两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种。
2.根据权利要求1所述的靶向定植的益生菌粉,其特征在于,两歧双歧杆菌、嗜热链球菌、嗜酸链球菌、长双歧杆菌和德式乳杆菌保加利亚亚种的质量比为2-3:1-2:1-3:1-2:1-1.5。
3.根据权利要求1所述的靶向定植的益生菌粉,其特征在于,所述益生元包括水苏糖和低聚半乳糖。
4.根据权利要求3所述的靶向定植的益生菌粉,其特征在于,水苏糖和低聚半乳糖的质量比为1:2-3,所述水苏糖与两歧双歧杆菌的质量比为4-7:1-2。
5.根据权利要求1所述的靶向定植的益生菌粉,其特征在于,所述包埋层包括聚-L-精氨酸和壳聚糖。
6.根据权利要求5所述的靶向定植的益生菌粉,其特征在于,聚-L-精氨酸和壳聚糖的质量比为1:2-4,所述壳聚糖与两歧双歧杆菌的质量比8-10:1-2。
7.根据权利要求1所述的靶向定植的益生菌粉,其特征在于,所述益生菌粉中活菌量为109-1010CFU/g。
8.根据权利要求1-7任一项所述的靶向定植的益生菌粉的制备方法,其特征在于,包括以下步骤:
S1、菌体制备:将益生菌的菌种活化后培养,生长至稳定期终止发酵,离心后收集菌体;
S2、菌悬液制备:在菌体中加入益生元得到菌悬液;
S3、包埋层制备:将菌悬液与包埋层混合搅拌,得到单层微囊菌液;
S4、菌粉制备:将单层微囊菌液冻干处理,制得靶向定植的益生菌粉。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010819662.7A CN112006285A (zh) | 2020-08-14 | 2020-08-14 | 一种靶向定植的益生菌粉及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010819662.7A CN112006285A (zh) | 2020-08-14 | 2020-08-14 | 一种靶向定植的益生菌粉及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112006285A true CN112006285A (zh) | 2020-12-01 |
Family
ID=73504534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010819662.7A Withdrawn CN112006285A (zh) | 2020-08-14 | 2020-08-14 | 一种靶向定植的益生菌粉及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112006285A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112715948A (zh) * | 2020-12-17 | 2021-04-30 | 新希望乳业股份有限公司 | 一种高活性益生菌晶球及其制备方法和应用 |
-
2020
- 2020-08-14 CN CN202010819662.7A patent/CN112006285A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112715948A (zh) * | 2020-12-17 | 2021-04-30 | 新希望乳业股份有限公司 | 一种高活性益生菌晶球及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100360658C (zh) | 肠道微生态制剂及其制备方法 | |
Kailasapathy et al. | L. acidophilus and Bifidobacterium spp.-their therapeutic potential and survival in yogurt | |
CN100386427C (zh) | 双歧杆菌和含有它们的制品 | |
EP1539927B1 (en) | Probiotic bacterium: lactobacillus fermentum | |
CN100469869C (zh) | 一种肠道益生菌包埋保护方法 | |
CN103189499B (zh) | 乳酸菌和/或双歧杆菌的存活能力提高剂 | |
CN108783462A (zh) | 一种肠道益生菌制剂的工业生产方法 | |
CZ300143B6 (cs) | Kmen Lactobacillus, jeho použití a výrobek jej obsahující | |
EP1867238B1 (en) | Feeding stuff composition comprising proliferation promoting agent for bifidus bacteria and use of the same | |
EP1840205B1 (en) | Bifidobacterium lactis 668 strain used as a component for food products, starters, medicinal and cosmetic agents | |
CN113826692A (zh) | 一种益生菌固体饮料及其制备方法 | |
KR101000364B1 (ko) | 생존율 증강용 이중 코팅 방법 | |
JP2020174667A (ja) | タンパク質加水分解物を用いたタンパク質−多糖類二重コーティング乳酸菌の製造方法 | |
CN111635875A (zh) | 一种长双歧杆菌cz70及其制备活菌型黑莓果浆的方法 | |
CN102077932A (zh) | 一种富含高活性肠道益生菌营养果冻的制作方法 | |
Fouad et al. | Bio-Labneh fortified with functional microcapsules filled with chickpea flour and probiotics | |
CN111685255B (zh) | 一种增强免疫功能的益生菌固体饮料及其制备方法 | |
CN112006285A (zh) | 一种靶向定植的益生菌粉及其制备方法 | |
WO2011068398A1 (en) | Probiotic composition obtained from lactobacillus plantarum strains ul4, tl1, rs5, r111, rg14 or combinations thereof | |
CN101574375B (zh) | 一种乳酸菌保健胶囊及其制备方法 | |
CN111345473A (zh) | 一种含卵黄抗体IgY的益生菌组合物及应用制剂 | |
CN111972669A (zh) | 一种增强免疫力的益生菌粉及其制备方法 | |
RU2264450C2 (ru) | Биопрепарат "бифистим для взрослых" для профилактики и лечения дисбактериозов и инфекционных болезней желудочно-кишечного тракта у людей старше 12 лет, биологически активная добавка к пище " бифистим для взрослых" для профилактики дисбактериозов и восстановления микрофлоры желудочно-кишечного тракта после антибиотикотерапии и других неблагоприятных воздействий у людей старше 12 лет и консорциум бифидобактерий для коррекции микрофлоры желудочно-кишечного тракта у людей старше 12 лет | |
CN114468305B (zh) | 一种缓解过度运动引起的不良反应的益生菌组合物及应用 | |
EP4361280A1 (en) | Food in controlled dynamic fermentation for bacteriostasis of beneficial microorganisms, keeping them alive and metabolically active for human consumption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201201 |